Author: admin

• Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) division and reported third-quarter earnings, with sales reaching US$26.33 million and a net loss of US$30.41 million for the period ended September 30, 2025.

• This move marks a business realignment to concentrate on the core surgical segment, with management expecting THP wind-down costs to conclude by the end of 2025 and further resource shifts to support main operations.

• We’ll explore how the decision to exit THP and focus on core surgical products influences Sanara MedTech’s investment outlook.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

To be a Sanara MedTech shareholder, you need to believe in the potential of its core surgical segment to drive future growth and profitability, especially as the company pivots away from digital health. The decision to discontinue the THP division directly addresses one of the short-term risks, persistent net losses and resource drag, while sharpening focus on the surgical business, which remains the primary catalyst for near-term improvement. The move does not materially change competitive or market risks, but it may impact resource allocation and operational priorities in the coming quarters. Among recent announcements, the company’s accelerated growth in its distributor and healthcare facility network is particularly relevant. This expanded reach could support higher sales volumes for Sanara’s proprietary surgical products and help offset both the transitional costs of winding down THP and the ongoing pressure from limited portfolio diversification. But on the flip side, investors should be aware that Sanara’s continued heavy focus on a narrow range of surgical wound care products means that…

Read the full narrative on Sanara MedTech (it’s free!)

Sanara MedTech’s outlook anticipates $144.9 million in revenue and $1.9 million in earnings by 2028. This scenario is based on a 14.2% annual revenue growth rate and an $11.8 million increase in earnings from the current -$9.9 million.

Uncover how Sanara MedTech’s forecasts yield a $41.00 fair value, a 90% upside to its current price.

Three distinct fair value estimates from the Simply Wall St Community fall between US$18.41 and US$41. With investors split on valuation, pay close attention to ongoing net losses and how business realignment could affect future earnings.

Explore 3 other fair value estimates on Sanara MedTech – why the stock might be worth 15% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Sanara MedTech research is our analysis highlighting 1 key reward that could impact your investment decision.

• Our free Sanara MedTech research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Sanara MedTech’s overall financial health at a glance.

Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SMTI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

• Earlier this week, Fluence Energy reported it expects fiscal year 2025 revenues to meet only the lower end of its prior guidance, citing slower-than-expected production ramp-up at new US manufacturing facilities and resulting delays set to affect fiscal year 2026.

• An important development is the company’s projection that these US sites will reach full capacity by year-end, which may enhance future delivery capabilities and strengthen Fluence’s domestic content position for its energy storage products.

• We’ll examine how the manufacturing delays and revised guidance may reshape Fluence Energy’s investment narrative and future growth outlook.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

To be a shareholder in Fluence Energy, you need confidence in the decades-long shift toward grid-scale battery storage and the company’s ability to scale domestic production to capitalize on rising electrification and clean energy demand. This week’s lowered revenue guidance linked to US facility production delays directly impacts the timeline of the company’s most important short-term catalyst, achieving reliable, resilient US-based supply, and magnifies the biggest current risk: further disruption from supply chain or policy uncertainty. While management reaffirms capacity ramp by year-end, the delay is meaningful for near-term delivery expectations.

The September 2025 announcement of Fluence’s first shipment of lithium-ion battery systems using U.S.-made components directly ties into the company’s pivot to domestic content, which remains central to its eligibility for incentives and its cost competitiveness. This milestone, once full plant utilization is realized, is critical for unlocking deferred contract revenue and reducing risk exposure to ongoing tariff volatility. However, for investors, an essential consideration remains…

Read the full narrative on Fluence Energy (it’s free!)

Fluence Energy’s narrative projects $4.2 billion in revenue and $97.9 million in earnings by 2028. This requires 19.5% yearly revenue growth and a $116.3 million increase in earnings from the current level of $-18.4 million.

Uncover how Fluence Energy’s forecasts yield a $10.53 fair value, a 41% downside to its current price.

Seven individual fair value estimates from the Simply Wall St Community for Fluence Energy span from US$10.53 to US$25.75 per share, showing wide disagreement in expectations. With production delays now affecting near-term revenue and profit timing, your view on supply chain execution could make all the difference, see how others approach the stock and weigh up the various arguments for yourself.

Explore 7 other fair value estimates on Fluence Energy – why the stock might be worth 41% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FLNC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Gartner (NYSE:IT) has sparked conversation across enterprise circles after releasing new forecasts about artificial intelligence’s sweeping impact on the workforce. The company’s latest research is drawing interest for its clear look at how AI could reshape job roles, IT work, and digital infrastructure strategies.

See our latest analysis for Gartner.

This wave of AI research comes on the heels of a busy period for Gartner, with the company recently announcing an $800 million senior notes offering and updating its full-year revenue outlook upward. In the past year, however, Gartner’s share price return has slumped by 52.2%, and the total shareholder return sits even lower at -55.8%. This underscores fading momentum despite strategic moves and robust thought leadership. Long-term holders have still enjoyed a positive 51.4% total return over five years, but recent performance highlights the increased uncertainty and risk perception reflected in the company’s valuation.

If Gartner’s shifting trajectory has you rethinking your next move, this could be the perfect moment to broaden your search and discover fast growing stocks with high insider ownership

With a year of falling returns but a solid history and signs of healthy growth, the question now is whether Gartner’s recent setbacks are masking an undervalued opportunity or if the market has already taken its future prospects into account.

Compared to Gartner’s last close price of $231.03, the most popular narrative’s fair value estimate of $285.45 reflects a significant gap. This discrepancy highlights what analysts believe are the drivers behind Gartner’s true worth.

*The rapid increase in enterprise adoption of AI, digital transformation, cybersecurity, and complex IT strategies is driving rising client demand for Gartner’s proprietary insights across multiple functions and industries. This supports potential long-term revenue acceleration as enterprises seek trusted guidance for mission-critical initiatives.*

Read the complete narrative.

Want to know what’s powering this bold upside? The market’s current view does not account for a future shaped by transformative digital investments and a strategic change in Gartner’s client relationships. The real engine behind the narrative valuation relies on shifting earnings, margins, and sharp revenue expectations. Which forecasted trend tips the scale? Crack open the full story to see the hidden math that justifies this fair value call.

Result: Fair Value of $285.45 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, ongoing cost-cutting by clients and the rapid rise of open-source AI tools could put pressure on Gartner’s recurring revenues and present challenges to the long-term upside case.

Find out about the key risks to this Gartner narrative.

Feel like a different story is unfolding, or want to examine the numbers on your own terms? You can dive in and craft your own view in just a few minutes: Do it your way

A great starting point for your Gartner research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Smart investors never settle for what’s familiar. Expand your opportunities and get ahead of the next trend by tapping into curated lists of companies reshaping the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com